Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation

GARY E. DUNCAN, SEIYA MIYAMOTO, and JEFFREY A. LIEBERMAN

Department of Psychiatry, School of Medicine, University of North Carolina Chapel Hill, North Carolina

Received December 14, 2002; accepted February 18, 2003

ABSTRACT

The fact that chronic administration of typical and atypical antipsychotic drugs is required for optimal therapeutic response suggests that drug-induced adaptive neurochemical changes contribute to their mechanism of action. In the present study, the effects of chronic and acute haloperidol and olanzapine were compared on ketamine-induced activation of select brain regions, as reflected by altered regional 14C-2-deoxyglucose (2-DG) uptake. Rats were injected once daily with haloperidol (1 mg/kg) or olanzapine (10 mg/kg) for 21 days, and 20 to 24 h after the final injection was challenged with saline or ketamine (25 mg/kg). The washout period was used to test the effects of chronic drug treatment without the influence of acute drug administration. In vehicle-treated rats, ketamine increased 2-DG uptake in select brain regions, including medial prefrontal cortex, nucleus accumbens, caudate putamen, stratum lacunosum-moleculare of hippocampus, and basolateral nucleus of the amygdala. This selective activation was attenuated by prior chronic treatment with both haloperidol and olanzapine. After acute treatment, olanzapine, but not haloperidol, blocked the ketamine-induced activation of 2-DG uptake. These data suggest that both haloperidol and olanzapine can induce adaptive responses that counteract effects of ketamine. However, the differences observed in the acute effects of the two drugs in the ketamine challenge model suggest that different mechanisms could be responsible for their common chronic action of attenuating ketamine-induced brain metabolic activation.

Psychotomimetic effects of NMDA receptor antagonists in humans suggest that reduced NMDA receptor function may contribute to the pathophysiology of schizophrenia. Antagonists of the NMDA receptor such as ketamine and phencyclidine (PCP) induce a spectrum of behavioral effects that mimic positive, negative, and cognitive symptoms of schizophrenia (Luby et al., 1959; Cohen et al., 1962; Krystal et al., 1994; Malhotra et al., 1996; Lahti et al., 2001). Furthermore, in stabilized schizophrenic patients, ketamine can precipitate positive symptoms that are remarkably similar to those experienced during active phases of the patient’s illness (Lahti et al., 1995a,b; Malhotra et al., 1997). The human experience with NMDA antagonists provides the foundation for the NMDA receptor hypofunction hypothesis of schizophrenia (Javitt and Zukin, 1991; Olney and Farber, 1995; Coyle, 1996).

Preclinical studies of the effects of antipsychotic drugs in paradigms involving challenge with NMDA receptor antagonists provide support for the NMDA receptor hypofunction hypothesis. Extensive preclinical data demonstrate differential effects of acutely administered “typical” antipsychotics and “atypical” antipsychotic drugs on responses to NMDA antagonists. Although there is no universal consensus on precise definitions for typical and atypical antipsychotics, the typical drugs are generally considered those whose primary mechanism is D2 dopamine blockade (e.g., haloperidol, chlorpromazine). The atypical drugs are characterized by having more complex mechanisms of action, which are not fully understood and demonstrate clinical efficacy with reduced side effects (e.g., clozapine, olanzapine). In a wide range of preclinical models, some of the atypical drugs attenuate effects of NMDA antagonists but the typical drugs do not. For example, clozapine and olanzapine, but not haloperidol or raclopride, attenuate the electrophysiological effects of PCP in brain slices (Arvanov et al., 1997; Wang and Liang, 1998; Arvanov and Wang, 1999). Deficits in PPI and social behavior induced by NMDA antagonists (Bakshi et al., 1994; Corbett et al., 1995; Bakshi and Geyer, 1995) are attenuated by clozapine and olanzapine, but not by haloperidol or raclopride. However, Mansbach et al. (2001) did find that haloperidol reduced PCP-induced deficits in PPI but to a lesser extent than did clozapine and ziprasidone. In studies of ketamine-induced brain metabolic activation, clozapine and...
olanzapine, but not haloperidol, blocked the activating effect of ketamine (Duncan et al., 1998a, 2000). The well-documented acute effects of atypical antipsychotics on responses to NMDA antagonists suggest that counteracting the effects of NMDA hypofunction could contribute to therapeutic mechanisms of action of the atypical drugs.

In addition to studying acute effects of antipsychotics, it is important to characterize neurobiological effects of chronic drug administration in preclinical models, since chronic treatment with antipsychotic drugs is essential for optimal therapeutic response. The therapeutically relevant adaptive changes induced by chronic antipsychotic drug treatments are poorly understood. Defining neurobiological adaptations induced by chronic drug exposure could provide insight into therapeutic mechanisms of currently used drugs and suggests novel treatment strategies that would mimic or promote adaptive responses.

In some preclinical models, quite different effects are found after chronic compared with acute antipsychotic administration. For example, acute treatment with clozapine and olanzapine enhanced NMDA-evoked electrophysiological responses, but chronic treatment with the drugs reduced NMDA receptor sensitivity (Arvanov and Wang, 1999; Jardemark et al., 2000). Also, chronic haloperidol was shown to reduce PCP-induced alterations in PPI under conditions where acute administration of this typical antipsychotic did not affect PCP-induced PPI deficits (Pietraszek and Ossowska, 1998; Martinez et al., 2000).

In our previous studies of the effects of antipsychotics on ketamine-induced alterations in regional brain metabolism,

**Fig. 1.** Autoradiographic images of 2-DG uptake. Rats were injected with olanzapine (10 mg/kg) or haloperidol (1 mg/kg) once daily for 21 days and challenged with saline or ketamine 20 to 24 h after the final injection. The first treatment designation above the images refers to chronic treatment, and the second refers to the acute challenge. II/IV, layers 3 and 4 of the somatosensory cortex; Rspl, retrosplenial cortex; SLM, stratum lacunosum-moleculare of hippocampus; DG, molecular layer of the dentate gyrus.
acute effects of the antipsychotics were examined (Duncan et al., 1998a, 2000). The present investigation characterized the effects of chronic administration of haloperidol and olanzapine in the ketamine challenge-metabolic mapping paradigm.

Materials and Methods

Animals and Treatments. Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed under a 12 h light/dark cycle with lights on at 7:00 AM, and had continuous access to food and water. All procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of North Carolina Institutional Animal Care Committee.

For chronic studies, rats weighing initially 150 to 175 g were injected i.p. once daily for 21 days with vehicle (10 μl of 20% acetic acid/ml of 0.9% saline), haloperidol (1 mg/kg), or olanzapine (10 mg/kg). After 21 days of treatment, the rats in vehicle, haloperidol, and olanzapine groups weighed, respectively (grams, mean ± S.E.M.) 300 ± 7, 282 ± 7, and 253 ± 5. The [14C]-2-deoxyglucose
(2-DG) uptake assessments were made 20 to 24 h after the final injection in the series (see below). For acute studies, rats were injected i.p. with haloperidol (0.5 mg/kg), olanzapine (10 mg/kg), or vehicle 1 h before the 2-DG. These doses were chosen for the acute studies because preliminary experiments found that they were the minimal doses required to completely block the behavioral activation induced by ketamine. Acute administration of 0.5 mg/kg haloperidol produced catalepsy in 100% of rats.

Three to five days before the 2-DG injections, jugular catheters were implanted under pentobarbital anesthesia and exteriorized at the base of the neck, so the 2-DG could be administered i.v. with minimal stress on the day of the experiment. After surgery, catheters were flushed daily with 0.9% saline to acclimate rats to the handling involved in the experimental procedures. Rats were transported from the animal quarters to the laboratory 4 to 6 h before initiation of the 2-DG experiment, and the 2-DG was given 20 to 24 h after the final injection of antipsychotics or vehicle.

High Resolution Autoradiographic Analysis of $^{14}$C-2-DG Uptake. The high-resolution autoradiographic procedures for analysis of 2-DG uptake have been described in detail (Duncan et al., 1993, 1998b, 2000). Behavioral activation was evident within 2 min after ketamine injection in vehicle pretreated rats, and the 2-DG (300 mCi/mmol, 0.4 μCi/g b.wt.; American Radiolabeled Chemicals, St. Louis, MO) was administered via the jugular catheter 3 min after i.p. injection of ketamine or saline. Rats were killed by decapitation 5 min after the i.v. injection of 2-DG to ensure a constant behavioral state during the 2-DG uptake period. We have demonstrated that a 5-min survival period after i.v. injection of 2-DG is useful for the study of time-limited behavioral events (Duncan et al., 1993, 1998a,b, 2000). Brains were frozen on an aluminum block cooled with liquid nitrogen and stored at −80°C until sectioned. Kodak SR Industrex film was cut into rectangular pieces approximately 3/4 the length of microscope slides and glued to one end of the slides with silicone adhesive. Cryostat sections (10 μm) of the brains were thaw-mounted onto the slide-mounted film under safe-light conditions and stored in light-tight desiccator boxes at room temperature for exposure periods of 6 weeks. The autoradiograms produced by thaw-mounting sections onto the high-resolution film were used for photographic documentation of 2-DG uptake patterns. For quantitative analysis, other sections were mounted onto microscope slides and exposed to Kodak Industrial T film in X-ray cassettes, along with $^{14}$C microscale standards (Amersham Biosciences Inc., Piscataway, NJ) for 2 weeks.

Autoradiograms were digitized with a high-resolution transparency scanner (Linotype-Hell; Saphir Ultra, Happauge NY) and analyzed with NIH Image software. Thirteen brain regions were chosen for quantitative evaluation based on our previous investigations of the effects of ketamine and antipsychotic drugs on 2-DG uptake. The regions chosen for study were previously shown to exhibit ketamine-induced increases in 2-DG uptake (medial prefrontal cortex (prelimbic cortex of Paxinos and Watson, 1997), anterior cingulate cortex, retrosplenial cortex, nucleus accumbens, caudate putamen, basolateral amygdala, and the dentate molecular layer and stratum lacunosum-moleculare of the hippocampus), as well as “control” regions (lateral frontal cortex (somatosensory cortex), medial septum, ventromedial hypothalamus, and CA3 and CA1 stratum radiatum) where no effects of ketamine were expected. Each of the 13 brain regions was analyzed in four sections for each animal and each treatment condition by observers blind to treatment conditions.

Statistics. PC-based SYSTAT software (version 9.0; SPSS, Chicago IL) was used for statistical analysis. A separate analysis of variance (ANOVA) was performed for each brain region for the three separate experiments of the study (i.e., chronic olanzapine and haloperidol, acute olanzapine, and acute haloperidol). Where significant effects were indicated in the ANOVA ($p < 0.05$), a set of planned comparisons was made by Tukey’s tests. The specific planned comparisons were chosen to assess whether the antipsychotic drugs...
alone altered 2-DG uptake or whether they altered the effects of ketamine on 2-DG uptake.

**Results**

**Behavioral and Brain Metabolic Responses to Ketamine after Chronic Haloperidol and Olanzapine.** Rats were tested 20 to 24 h after the final injection in the chronic series. After saline injection, there was no obvious difference in the behavior of rats treated chronically with haloperidol or olanzapine compared with controls. In all vehicle-treated rats, ketamine (25 mg/kg) induced a typical behavioral response of staggered locomotion and repetitive stereotypic side-to-side head movements. For rats in the chronic olanzapine and haloperidol groups, the behavioral activation induced by ketamine was reduced. After olanzapine and haloperidol, respectively, 5/9 and 7/9 rats exhibited no ketamine-induced behavioral activation as defined by staggered locomotion and stereotypic head movements. For the rats in the chronic olanzapine and haloperidol groups that did show a response to ketamine, the behavioral activation was noticeably less vigorous in comparison to the rats injected chronically with vehicle and challenged with ketamine.

Ketamine induced a neuroanatomically selective activation that was significantly reduced by chronic treatment with haloperidol and olanzapine. Autoradiograms of rats in the different treatment groups are shown in Fig. 1, and quantitative data are shown in Fig. 2. In vehicle-treated rats, ketamine induced a robust activation of 2-DG uptake in the medial prefrontal cortex, anterior cingulate cortex, retrosplenial cortex, nucleus accumbens, caudate putamen, basolateral nucleus of the amygdala, and stratum lacunosum-molecular of the hippocampus. Chronic treatment with both haloperidol and olanzapine significantly reduced the ketamine-induced activation in all these regions except the nucleus accumbens. For the nucleus accumbens there was a trend for both haloperidol and olanzapine to reduce the effects of ketamine, but the differences were not significant at the p < 0.05 level. In regions that did not show increased 2-DG uptake in response to ketamine, the antipsychotics did not alter 2-DG uptake compared with the vehicle-injected controls.

**Behavioral and Brain Metabolic Responses to Ketamine after Acute Haloperidol and Olanzapine.** In the rats injected acutely with haloperidol (0.5 mg/kg) or olanzapine (10 mg/kg) and then injected with saline 1 h later, increased 2-DG uptake was observed in the lateral habenula, and decreased relative uptake was observed in the retrosplenial cortex (Figs. 3 and 4). Other regions assessed did not show significant differences in relative 2-DG uptake. Administration of both haloperidol and olanzapine, 1 h before ketamine, completely blocked ketamine-induced behavioral activation in all rats. In contrast to the similar effects of the two drugs on ketamine-induced behavioral activation, only olanzapine blocked ketamine-induced brain metabolic activation (Figs. 2 and 3).

**Discussion**

Subanesthetic doses of ketamine induce marked alterations in regional patterns of brain metabolism. As observed in our previous studies with rats (Duncan et al., 1998a,b, 2000) and mice (Miyamoto et al., 2000, 2001; Duncan et al., 2002), the present work found selective ketamine-induced activation of the limbic cortical regions, subregions of the hippocampus, nucleus accumbens, caudate putamen, and basolateral amygdala. Chronic administration of haloperidol and olanzapine attenuated the brain metabolic activation induced by ketamine. The mechanisms for NMDA antagonist-induced brain metabolic and behavioral activation are poorly understood but may paradoxically involve glutamatergic activation. Subanesthetic doses of NMDA antagonists increase brain extracellular fluid levels of glutamate (Bustos et al., 1992; Moghaddam et al., 1997), presumably by disinhibitory mechanisms (Olney and Farber, 1995; Greene, 2001; Farber et al., 2002). These excitatory amino acids could then activate non-NMDA receptors (Moghadan et al., 1997) as well as NMDA receptors unblocked by low doses of ketamine. In contrast to the increase in glutamate release by subanesthetic doses of ketamine, anesthetic doses of the drug decrease glutamate levels (Moghaddam et al., 1997). The effects of different doses of ketamine on excitatory amino acid levels are consistent with our observations of increased 2-DG uptake in response to a subanesthetic dose and global reduction in 2-DG uptake in response to an anesthetic dose of ketamine (Duncan et al., 1998b). Whether chronic antipsychotic administration enhances NMDA receptor function or attenuates the effects of ketamine by modulating glutamate or other neurotransmitter systems will require further study. The acute actions of antipsychotic drugs to counteract effects

---

**TABLE 1**

Major findings in studies examining effects of chronic antipsychotic drug treatments on glutamate receptor binding and mRNA expression

<table>
<thead>
<tr>
<th>Study</th>
<th>Major Effects after Chronic Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tasci et al., 2001</td>
<td>Olanzapine increased AMPA mRNA (GluB and GluC) in hippocampus. No effect on NMDA or metabotropic</td>
</tr>
<tr>
<td>Chen and Gurling, 1999</td>
<td>receptor subunits message in hippocampus. In striatum, no effect of olanzapine on NMDA, AMPA, or metabotropic mRNA.</td>
</tr>
<tr>
<td>Ossowska et al., 1999</td>
<td>Clozapine and haloperidol had no effect on MK801 binding but both increased °H-CGP-39653 (competitive</td>
</tr>
<tr>
<td>Giardino et al., 1997</td>
<td>AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.</td>
</tr>
<tr>
<td>Farber et al., 1997</td>
<td>Haloperidol and olanzapine increased NR1 and NR2A-C mRNA in striatum.</td>
</tr>
<tr>
<td>Fitzgerald et al., 1995</td>
<td>Haloperidol, but not clozapine, increased NR1 protein in striatum.</td>
</tr>
<tr>
<td>Ulas et al., 1993</td>
<td>Haloperidol increased NMDA binding in cortex but not hippocampus.</td>
</tr>
</tbody>
</table>

AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.
of NMDA antagonists do not apparently involve reduced presynaptic glutamate release in the medial prefrontal cortex of the rat, since the drugs did not affect PCP-induced glutamate releases as assessed by microdialysis (Adams and Moghaddam, 2001). However, there are no data available for the effects of chronic antipsychotic drug treatment on NMDA antagonist-induced release of glutamate.

In the present study, one purpose of using a 20 to 24 h washout period after the final injection in the chronic series was to minimize the acute pharmacological actions of olanzapine and haloperidol at the time of ketamine challenge. Both drugs produce sedative effects after acute administration, which could confound interpretation of results. The plasma half-life of both clozapine and haloperidol in rats is approximately 1.5 h (Cheng and Paalzow, 1992; Baldessarini et al., 1993). Therefore, 24 h after the final injection, there should be minimal circulating antipsychotic drug at the time of the ketamine challenge. There were no apparent behavioral effects of the drugs in rats 20 to 24 h after the final drug injection under control conditions. Also, the characteristic activation of the lateral habenula after acute haloperidol and olanzapine treatment was not seen after the washout period. However, the behavioral and brain metabolic responses to ketamine challenge were attenuated 20 to 24 h after the last injection of both haloperidol and olanzapine. These data suggest that adaptive changes were induced by both drugs to counteract the effects of ketamine.

In many model systems based on acute effects of antipsychotic drugs, treatment with haloperidol is ineffective or less effective than clozapine and other atypical antipsychotics in reversing effects of NMDA antagonists (see Introduction). However, in studies of PCP-induced deficits in PPI, chronic administration of haloperidol antagonized effects of PCP (Pietraszek and Ossowska, 1998; Ossowska et al., 2000). Thus after chronic administration, haloperidol can block disruptive behavioral effects of NMDA antagonists. Such findings are similar to the results of the present investigation showing that chronic (but not acute) administration of haloperidol attenuated effects of ketamine. Since acute administration of olanzapine reduced ketamine-induced brain metabolic activation but acute treatment with haloperidol did not, it is possible that the effects of the two drugs observed after chronic treatment could involve different mechanisms.

In contrast to selective attenuation of PCP-induced PPI deficits by atypical antipsychotics, amphetamine-induced disruption of PPI is consistently reported to be reduced by acute administration of both typical and atypical antipsychotic drugs (for review, see Geyer et al., 2001). However, after chronic administration, neither the typical nor atypical antipsychotics affect the altered sensory gating induced by amphetamine (Andersen and Pouzet, 2001). As noted above, chronic administration of both typical and atypical antipsychotics attenuated PCP-induced deficits in PPI. Thus, in the PPI model of sensory gating, adaptive changes induced by chronic antipsychotic treatments appear to attenuate effects of NMDA antagonists but not effects of amphetamine.

Mechanisms responsible for the observed effects of chronic haloperidol and olanzapine on responses to NMDA antagonists could involve alterations in postsynaptic glutamate receptors. Administration of both typical and atypical antipsychotic drugs can alter glutamate receptor binding and expression of specific subunits of the receptor (see Table 1). A detailed discussion of the complex results of these studies is beyond the scope of the present study, but major findings are summarized in Table 1. Both increases and decreases in binding sites and subunit expression have been reported. It is not known whether such changes reflect increased or decreased function of glutamate receptors.

Studies that examined functional responses to NMDA after chronic antipsychotic treatments suggest that both typical and atypical drugs induce an adaptive reduction in NMDA receptor sensitivity. Ossowska (1995) found that chronic administration of haloperidol attenuated turning behavior produced by microinjection of NMDA into the caudate putamen. Also, Jardemark et al. (2000) found that 21 days of treatment with haloperidol, clozapine, and olanzapine reduced the electrophysiological sensitivity to NMDA in slices of the medial prefrontal cortex. The treatment duration and washout period (24 h) in the study by Jardemark et al. (2000) were the same as those used in the present study. One interpretation of the results of the present study is that reduced NMDA receptor function, in circuits responsible for ketamine-induced metabolic activation, is related to the attenuated response to ketamine observed after chronic haloperidol and olanzapine treatments.

As noted previously, it may seem paradoxical that reduced NMDA receptor function could counteract effects of an NMDA receptor antagonist. However, the neuroanatomically specific brain metabolic response to ketamine apparently involves activation of glutamatergic neurotransmission, since glutamate provides the primary excitatory drive in the brain. It will be of interest in future studies to determine whether the attenuation of the effects of NMDA antagonists by chronic administration of typical and atypical antipsychotic drugs involves molecular alterations in NMDA receptors in specific cell types and circuits or altered monoamine-glutamate interactions.

References
Coye JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Har- 


Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, and Dunn RW 

(1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate 


Duncan GE, Johnson KB, and Breeze GR (1993) Topographic patterns of brain 

activity in response to swim stress: Assessment by 2-deoxyglucose uptake and 


Duncan GE, Leipzig JN, Mailman BB, and Lieberman JA (1998a) Differential effects 

of clonazepam and haloperidol on ketamine-induced brain metabolic activation. 

Brain Res 812:65–75.

Duncan GE, Miyamoto S, Gu HB, Lieberman JA, Koller BH, and Snouwaert JN 

(2000) Comparison of the effects of clonazepam, risperidone and olanzapine on 

ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 

295:8–14.

Duncan GE, Moy SS, Knapp DM, Mueller RA, and Breeze GE (1998b) Metabolic 

mapping of the rat brain after subanesthetic doses of ketamine: potential rele-


Farber NB, Kim SH, Dikranian K, Jiang XP, and Heinzel C (2002) Receptor me-

chisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 

7:52–43.

Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, and Nestler EJ (1995) Regu-

lation of cortical and subcortical glutamate receptor subunit expression by anti-


studies of prepulse inhibition models of sensorimotor gating deficits in schizophre-


Giardino L, Bortolotti F, Orazio C, Pozza M, Monteleone P, Calza L, and Maj M 

(1997) Effect of chronic clonazepam administration on [IIIUMGB1]– binding sites in 


Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, 


with either clonazepam, olanzapine or haloperidol produces a hypoensive response 


Javitt DC and Zukin SR (1991) Recent advances in the phenylcycloyle model of 


Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Breimer JD, Heninger 

GR, Bowers MB Jr, and Charney DS (1994) Subanesthetic effects of the noncom-

petitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, 


Lahti AC, Holcomb HH, Medoff DR, and Tamminga CA (1995a) Ketamine activates 

psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:809–872.

Lahti AC, Koffel B, LaPorte D, and Tamminga CA (1995b) Subanesthetic doses of 

ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 12:9–19.


ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 


Malhotra AK, Pinhas DA, Adler CM, Elman I, Clifton A, Pickar D, and Breier A 

(1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive im-

pairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141– 

150.

Malhotra AK, Pinhas DA, Weingartner H, Sirocco K, Missar CD, Pickar D, and Breier 

A (1996) NMDA receptor function and human cognition—the effects of ketamine in 


Mansbach RS, Carver J, and Zorn SH (2001) Blockade of drug-induced deficits in 

prepulse inhibition of acoustic startle by ziprasidone. Pharmacol, Biochem Behav 


and “late” effects of sustained haloperidol on apomorphine- and phencyclidine-


MK-801 and amphetamine on regional brain 2-deoxyglucose uptake in freely 


Miyaoto S, Mailman BB, Lieberman JA, and Duncan GE (2001) Blunted brain 

metabolic response to ketamine in mice lacking D1A dopamine receptors. Brain 


Mohgadlam B, Adams B, Verman A, and Daly D (1997) Activation of glutamatergic 

neurotransmission by ketamine—a novel step in the pathway from NMDA recep-

tor blockade to dopaminergic and cognitive disruptions associated with the 


Olney JW and Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. 

Arch Gen Psychiatry 52:998–1007.

Ossowska K (1995) The subsensitivity of striatal glutamate receptors induced by 


haloperidol and clonazapine administration increases the number of cortical NMDA 


Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajazkowski W, Walfarth S, and 


Press, New York.

Pietraszek M and Ossowska K (1998) Chronic treatment with haloperidol diminishes 

the phencyclidine-induced sensorimotor gating deficit in rats. Neuropsychobiology 

25:467–471.

Riva MA, Tascedda F, Lovati E, and Racagni G (1997) Regulation of NMDA receptor 

subunit messenger RNA levels in the rat brain following acute and chronic expo-


Tarazi F, Florijn WJ, and Creese I (1996) Regulation of NMDA glutamate receptors 

following subchronic and chronic treatment with typical and atypical antipsychotics. 


Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colazi A, Bravi D, Carra S, 

Racagni G, and Riva MA (2001) Modulation of glutamate receptors in response to 


Tascedda F, Lovati E, Blom JM, Muzzio P, Brunello N, Racagni G, and Riva MA 

(1999) Regulation of ionotropic glutamate receptors in the rat brain in response to 

the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychophar-

macology 21:211–217.


binding to NMDA receptors in rat cortex. Neuroreport 4:1049–1051.

Wang RY and Liang X (1998) M100907 and clonazepam, but not haloperidol or raclo-

ride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal 

neurones of the rat medial prefrontal cortical slices. Neuropsychopharmacology 


Address correspondence to: Dr. Gary E. Duncan, Department of Psychiatry, 

CB #7090, University of North Carolina School of Medicine, Chapel Hill, 

NC 27599-7250. E-mail: gduncan@med.unc.edu.